Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921670 | 1.00 | MPI (0.45) | MPILMNAL3MBTL1TDP1 | |
| SCHEMBL2883546 | 0.97 | MPI (0.45) | MPILMNAL3MBTL1TDP1 | |
| SCHEMBL15874622 | 0.97 | MPI (0.45) | MPILMNAL3MBTL1TDP1 | |
| SCHEMBL8588218 | 0.91 | MPI (0.38) | MPILMNA | |
| SCHEMBL523990 | 0.90 | MPI (0.58) | MPI | |
| SCHEMBL9117419 | 0.90 | MPI (0.58) | MPI | |
| SCHEMBL987653 | 0.90 | MPI (0.58) | MPI | |
| SCHEMBL10588407 | 0.88 | MPI (0.42) | MPILMNAL3MBTL1TDP1 | |
| SCHEMBL17964362 | 0.87 | MPI (0.42) | MPI | |
| Galactose SCHEMBL18304348 | 0.85 | MPI (0.42) | MPILMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211740-A1 | SIRT1-SARNA COMPOSITIONS AND METHODS OF USE | BOOTSTRAP EUROPE 3.0 S.À R.L. (LU) | 2022-07-07 | — | — | US | disclosed |
| US-8642010-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | DYAX CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| CN-102630140-A | A system for transformation of the chloroplast genome of scenedesmus sp. and dunaliella sp. | SAPPHIRE ENERGY INC | 2012-08-08 | — | — | CN | disclosed |
| US-20100003195-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-1311162-B1 | BACILLUS THURIGIENSIS CRYSTAL PROTEIN HYBRIDS | SYNGENTA PARTICIPATIONS AG (CH) | 2005-06-01 | — | — | EP | disclosed |
| EP-1311162-A2 | BACILLUS THURIGIENSIS CRYSTAL PROTEIN HYBRIDS | Syngenta Participations AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002015701-A2 | BACILLUS THURINGIENSIS CRYSTAL PROTEIN HYBRIDS | SYNGENTA PARTICIPATIONS AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211740-A1 | SIRT1-SARNA COMPOSITIONS AND METHODS OF USE | SIRT1, SARM1, SARNP | MPI 3765/4885LMNA 195/4885L3MBTL1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.